Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 97 to 104 of 104 entries
Sorted by: Best Match Show Resources per page
Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction.

Annals of the New York Academy of Sciences

Rothman RB, Elmer GI, Shippenberg TS, Rea W, Baumann MH.
PMID: 29090820
Ann N Y Acad Sci. 1998 May;844(1):59-74. doi: 10.1111/j.1749-6632.1998.tb08222.x.

Combined dopamine (DA) and 5-hydroxytryptamine (5-HT) releasers such as phentermine (PHEN) and fenfluramine (FEN) are reported, in open label studies, to reduce craving for alcohol and cocaine and to prevent relapse. The objective of the studies reported here was...

Cite
Rothman RB, Elmer GI, Shippenberg TS, et al. Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. Ann N Y Acad Sci. 1998;844(1):59-74doi: 10.1111/j.1749-6632.1998.tb08222.x.
Rothman, R. B., Elmer, G. I., Shippenberg, T. S., Rea, W., & Baumann, M. H. (1998). Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. Annals of the New York Academy of Sciences, 844(1), 59-74. https://doi.org/10.1111/j.1749-6632.1998.tb08222.x
Rothman, Richard B, et al. "Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction." Annals of the New York Academy of Sciences vol. 844,1 (1998): 59-74. doi: https://doi.org/10.1111/j.1749-6632.1998.tb08222.x
Rothman RB, Elmer GI, Shippenberg TS, Rea W, Baumann MH. Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. Ann N Y Acad Sci. 1998 May;844(1):59-74. doi: 10.1111/j.1749-6632.1998.tb08222.x. PMID: 29090820.
Copy Download .nbib Format: NLM
Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Jo HS, Wang SM, Kim JJ.
PMID: 30690949
Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):130-133. doi: 10.9758/cpn.2019.17.1.130.

Phentermine is a sympathomimetic amine, like amphetamine, which is one of the most often prescribed drugs for weight loss. Although exact mechanism of phentermine causing psychosis is still not clear, numerous reports already showed that phentermine can induce psychosis....

Cite
Jo HS, Wang SM, Kim JJ. Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report. Clin Psychopharmacol Neurosci. 2019;17(1):130-133doi: 10.9758/cpn.2019.17.1.130.
Jo, H. S., Wang, S. M., & Kim, J. J. (2019). Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 17(1), 130-133. https://doi.org/10.9758/cpn.2019.17.1.130
Jo, Hyun-Sic, et al. "Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 17,1 (2019): 130-133. doi: https://doi.org/10.9758/cpn.2019.17.1.130
Jo HS, Wang SM, Kim JJ. Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report. Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):130-133. doi: 10.9758/cpn.2019.17.1.130. PMID: 30690949; PMCID: PMC6361044.
Copy Download .nbib Format: NLM
Retrospective descriptive analysis of a managed care population with obesity.

Current medical research and opinion

Osterland A, King C, Kumar N, Mocarski M, Ramasamy A, Walker C, Darji H, Godley P.
PMID: 34643454
Curr Med Res Opin. 2021 Oct 23;1-7. doi: 10.1080/03007995.2021.1991900. Epub 2021 Oct 23.

OBJECTIVES: To reveal the extent of obesity in a single healthcare system and provide a blueprint for other health systems to perform similar analyses, this study describes characteristics and weight change patterns of patients classified with overweight and obesity...

Cite
Osterland A, King C, Kumar N, et al. Retrospective descriptive analysis of a managed care population with obesity. Curr Med Res Opin. 2021;1-7doi: 10.1080/03007995.2021.1991900.
Osterland, A., King, C., Kumar, N., Mocarski, M., Ramasamy, A., Walker, C., Darji, H., & Godley, P. (2021). Retrospective descriptive analysis of a managed care population with obesity. Current medical research and opinion, 1-7. https://doi.org/10.1080/03007995.2021.1991900
Osterland, Andrew, et al. "Retrospective descriptive analysis of a managed care population with obesity." Current medical research and opinion vol. (2021): 1-7. doi: https://doi.org/10.1080/03007995.2021.1991900
Osterland A, King C, Kumar N, Mocarski M, Ramasamy A, Walker C, Darji H, Godley P. Retrospective descriptive analysis of a managed care population with obesity. Curr Med Res Opin. 2021 Oct 23;1-7. doi: 10.1080/03007995.2021.1991900. Epub 2021 Oct 23. PMID: 34643454.
Copy Download .nbib Format: NLM
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.

Blood pressure monitoring

Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd PN, White WB.
PMID: 34699409
Blood Press Monit. 2021 Oct 25; doi: 10.1097/MBP.0000000000000572. Epub 2021 Oct 25.

OBJECTIVES: To characterize the blood pressure (BP) profile of the new β3-adrenergic receptor agonist, vibegron, in patients with overactive bladder.METHODS: Patients were randomized to once-daily vibegron 75 mg or placebo for 28 days and underwent ambulatory BP monitoring. The...

Cite
Weber MA, Haag-Molkenteller C, King J, et al. Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Press Monit. 2021;doi: 10.1097/MBP.0000000000000572.
Weber, M. A., Haag-Molkenteller, C., King, J., Walker, A., Mudd, P. N., & White, W. B. (2021). Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood pressure monitoring, . https://doi.org/10.1097/MBP.0000000000000572
Weber, Michael A, et al. "Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial." Blood pressure monitoring vol. (2021). doi: https://doi.org/10.1097/MBP.0000000000000572
Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd PN, White WB. Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Press Monit. 2021 Oct 25; doi: 10.1097/MBP.0000000000000572. Epub 2021 Oct 25. PMID: 34699409.
Copy Download .nbib Format: NLM
The potential role of stimulants in treating eating disorders.

The International journal of eating disorders

Keshen A, Bartel S, Frank GKW, Svedlund NE, Nunes A, Dixon L, Ali SI, Kaplan AS, Hay P, Touyz S, Romo-Nava F, McElroy SL.
PMID: 34846763
Int J Eat Disord. 2021 Nov 30; doi: 10.1002/eat.23650. Epub 2021 Nov 30.

BACKGROUND: Many individuals with eating disorders remain symptomatic after a course of psychotherapy and pharmacotherapy; therefore, the development of innovative treatments is essential.METHOD: To learn more about the current evidence for treating eating disorders with stimulants, we searched for...

Cite
Keshen A, Bartel S, Frank GKW, et al. The potential role of stimulants in treating eating disorders. Int J Eat Disord. 2021;doi: 10.1002/eat.23650.
Keshen, A., Bartel, S., Frank, G. K. W., Svedlund, N. E., Nunes, A., Dixon, L., Ali, S. I., Kaplan, A. S., Hay, P., Touyz, S., Romo-Nava, F., & McElroy, S. L. (2021). The potential role of stimulants in treating eating disorders. The International journal of eating disorders, . https://doi.org/10.1002/eat.23650
Keshen, Aaron, et al. "The potential role of stimulants in treating eating disorders." The International journal of eating disorders vol. (2021). doi: https://doi.org/10.1002/eat.23650
Keshen A, Bartel S, Frank GKW, Svedlund NE, Nunes A, Dixon L, Ali SI, Kaplan AS, Hay P, Touyz S, Romo-Nava F, McElroy SL. The potential role of stimulants in treating eating disorders. Int J Eat Disord. 2021 Nov 30; doi: 10.1002/eat.23650. Epub 2021 Nov 30. PMID: 34846763.
Copy Download .nbib Format: NLM
Umbilical Cord Drug Screening in Multiple Births: Experience from a Reference Laboratory and Academic Medical Center.

Journal of analytical toxicology

Nelson HA, Wood KE, McMillin GA, Krasowski MD.
PMID: 34165142
J Anal Toxicol. 2021 Jun 24; doi: 10.1093/jat/bkab077. Epub 2021 Jun 24.

The objective of this study was to review the results of umbilical cord drug screening in twins and triplets (multiples) to compare drug(s) and/or drug metabolite(s) detected. Results that did not agree between multiples were considered mismatched and were...

Cite
Nelson HA, Wood KE, McMillin GA, et al. Umbilical Cord Drug Screening in Multiple Births: Experience from a Reference Laboratory and Academic Medical Center. J Anal Toxicol. 2021;doi: 10.1093/jat/bkab077.
Nelson, H. A., Wood, K. E., McMillin, G. A., & Krasowski, M. D. (2021). Umbilical Cord Drug Screening in Multiple Births: Experience from a Reference Laboratory and Academic Medical Center. Journal of analytical toxicology, . https://doi.org/10.1093/jat/bkab077
Nelson, Heather A, et al. "Umbilical Cord Drug Screening in Multiple Births: Experience from a Reference Laboratory and Academic Medical Center." Journal of analytical toxicology vol. (2021). doi: https://doi.org/10.1093/jat/bkab077
Nelson HA, Wood KE, McMillin GA, Krasowski MD. Umbilical Cord Drug Screening in Multiple Births: Experience from a Reference Laboratory and Academic Medical Center. J Anal Toxicol. 2021 Jun 24; doi: 10.1093/jat/bkab077. Epub 2021 Jun 24. PMID: 34165142.
Copy Download .nbib Format: NLM
Retrospective descriptive analysis of a managed care population with obesity.

Current medical research and opinion

Osterland A, King C, Kumar N, Mocarski M, Ramasamy A, Walker C, Darji H, Godley P.
PMID: 34643454
Curr Med Res Opin. 2022 Jan;38(1):83-89. doi: 10.1080/03007995.2021.1991900. Epub 2021 Oct 23.

OBJECTIVES: To reveal the extent of obesity in a single healthcare system and provide a blueprint for other health systems to perform similar analyses, this study describes characteristics and weight change patterns of patients classified with overweight and obesity...

Cite
Osterland A, King C, Kumar N, et al. Retrospective descriptive analysis of a managed care population with obesity. Curr Med Res Opin. 2021;38(1):83-89doi: 10.1080/03007995.2021.1991900.
Osterland, A., King, C., Kumar, N., Mocarski, M., Ramasamy, A., Walker, C., Darji, H., & Godley, P. (2022). Retrospective descriptive analysis of a managed care population with obesity. Current medical research and opinion, 38(1), 83-89. https://doi.org/10.1080/03007995.2021.1991900
Osterland, Andrew, et al. "Retrospective descriptive analysis of a managed care population with obesity." Current medical research and opinion vol. 38,1 (2022): 83-89. doi: https://doi.org/10.1080/03007995.2021.1991900
Osterland A, King C, Kumar N, Mocarski M, Ramasamy A, Walker C, Darji H, Godley P. Retrospective descriptive analysis of a managed care population with obesity. Curr Med Res Opin. 2022 Jan;38(1):83-89. doi: 10.1080/03007995.2021.1991900. Epub 2021 Oct 23. PMID: 34643454.
Copy Download .nbib Format: NLM
Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine.

American journal of therapeutics

Patel M, Daboul J, Iftikhar S, Burmeister C, Ambati A, Moukarbel G, Assaly R.
PMID: 34117142
Am J Ther. 2021 Jun 01; doi: 10.1097/MJT.0000000000001387. Epub 2021 Jun 01.

No abstract available.

Cite
Patel M, Daboul J, Iftikhar S, et al. Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine. Am J Ther. 2021;doi: 10.1097/MJT.0000000000001387.
Patel, M., Daboul, J., Iftikhar, S., Burmeister, C., Ambati, A., Moukarbel, G., & Assaly, R. (2021). Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine. American journal of therapeutics, . https://doi.org/10.1097/MJT.0000000000001387
Patel, Mitra, et al. "Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine." American journal of therapeutics vol. (2021). doi: https://doi.org/10.1097/MJT.0000000000001387
Patel M, Daboul J, Iftikhar S, Burmeister C, Ambati A, Moukarbel G, Assaly R. Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine. Am J Ther. 2021 Jun 01; doi: 10.1097/MJT.0000000000001387. Epub 2021 Jun 01. PMID: 34117142.
Copy Download .nbib Format: NLM
Showing 97 to 104 of 104 entries